Shots:

• Kyowa Kirin to receive up front- regulatory & commercial milestones along with royalties and a share of sublicensing income. The company also has an option to retain rights in Japan
• Cerecor to get exclusive rights for the development- manufacturing and commercialization of CERC-00 for all indications globally including the US- EU and Japan
• The expanded agreement involves all indications of CERC-00 including severe pediatric onset inflammatory bowel disease and ARDS (including COVID-19 ARDS)

  Ref: GlobeNewswire | Image: Bio Tuesdays